Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana

[1]  S. Sheth,et al.  Post Exposure Prophylaxis for Occupational Exposures to HIV and Hepatitis B: Our Experience of Thirteen Years at a Rural Based Tertiary Care Teaching Hospital of Western India. , 2016, Journal of clinical and diagnostic research : JCDR.

[2]  H. Leufkens,et al.  Outcomes of a Postexposure Prophylaxis Program at the Korle-Bu Teaching Hospital in Ghana , 2015, Journal of the International Association of Providers of AIDS Care.

[3]  C. Hamelmann,et al.  Correction: Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria , 2012, BMC Clinical Pharmacology.

[4]  George I Eluwa,et al.  Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria , 2012, BMC clinical pharmacology.

[5]  C. Leen,et al.  British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010 , 2010, HIV medicine.

[6]  M. Ardo,et al.  A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure , 2009 .

[7]  H. Ward,et al.  Predictive Validity of a Medication Adherence Measure in an Outpatient Setting , 2008, Journal of clinical hypertension.

[8]  Heather Husson,et al.  Prospective Cohort Study of HIV Post-Exposure Prophylaxis for Sexual Assault Survivors , 2008, Antiviral therapy.

[9]  Fanelo James Arens,et al.  Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. , 2007, The Cochrane database of systematic reviews.

[10]  R. Remien,et al.  Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model. , 2006, AIDS patient care and STDs.

[11]  A. Panlilio,et al.  Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[12]  R. Salamon,et al.  Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Montaner,et al.  Adverse effects of antiretroviral therapy for HIV infection. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  P. Kissinger,et al.  Patterns and Correlates of Discontinuation of the Initial HAART Regimen in an Urban Outpatient Cohort , 2003, Journal of acquired immune deficiency syndromes.

[15]  G. Ippolito,et al.  Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis , 2003, AIDS.

[16]  J. Gerberding.  Occupational Exposure to HIV in Health Care Settings , 2003 .

[17]  R. Hogg,et al.  Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. , 2002, Journal of acquired immune deficiency syndromes.

[18]  N. Ives,et al.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy , 2002, AIDS.

[19]  R. Mann,et al.  Prescription-event monitoring--recent progress and future horizons. , 2002, British journal of clinical pharmacology.

[20]  C. Rabaud,et al.  Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Panlilio,et al.  Experience of Healthcare Workers Taking Postexposure Prophylaxis After Occupational HIV Exposures: Findings of the HIV Postexposure Prophylaxis Registry , 2000, Infection Control & Hospital Epidemiology.

[22]  J. Anderson,et al.  Tolerability and side-effects of post-exposure prophylaxis for HIV infection , 2000, The Lancet.

[23]  E. Ricci,et al.  Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected Patients , 1999, Antiviral therapy.

[24]  D. Craven,et al.  Occupational exposure to HIV: experience at a tertiary care center. , 1998, Journal of occupational and environmental medicine.

[25]  D. Cardo,et al.  A Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure , 1998 .

[26]  D. Cardo,et al.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. , 1997, The New England journal of medicine.

[27]  M. Hirsch,et al.  Combination chemotherapy for human immunodeficiency virus-1. , 1997, The American journal of medicine.

[28]  C. Tamalet,et al.  Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. , 1997, The Journal of infectious diseases.

[29]  J. Tokars,et al.  Surveillance of HIV Infection and Zidovudine Use among Health Care Workers after Occupational Exposure to HIV-Infected Blood , 1993, Annals of Internal Medicine.

[30]  G. Ippolito,et al.  Postexposure HIV prophylaxis regimen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  F. Ncube,et al.  OCCUPATIONAL TRANSMISSION OF HIV , 2005 .

[32]  D. Henderson,et al.  Tolerability of Postexposure Antiretroviral Prophylaxis for Occupational Exposures to HIV , 2001, Drug safety.

[33]  J. Gerberding,et al.  Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. , 2001, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.